Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction

EPI Study Group
Chadi A Hage
Indiana University
Suresh Vedantham
Washington University School of Medicine in St. Louis
Mary Clare Derfler
Washington University School of Medicine in St. Louis
Paul Commean
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4

Part of the Medicine and Health Sciences Commons

Please let us know how this document benefits you.

Recommended Citation
EPI Study Group; Hage, Chadi A; Vedantham, Suresh; Derfler, Mary Clare; Commean, Paul; Spitznagel, Ed; Atkinson, Jeff; Despotis, George; and et al., "Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction." Transfusion medicine. 31, 4. 292 - 302. (2021).
https://digitalcommons.wustl.edu/oa_4/3018

This Open Access Publication is brought to you for free and open access by the Open Access Publications at Digital Commons@Becker. It has been accepted for inclusion in 2020-Current year OA Pubs by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Authors
EPI Study Group, Chadi A Hage, Suresh Vedantham, Mary Clare Derfler, Paul Commean, Ed Spitznagel, Jeff Atkinson, George Despotis, and et al.

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/oa_4/3018
Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction

The EPI Study Group | Chadi A. Hage1 | Julia Klesney-Tait2 | Keith Wille3 | Selim Arcasoy4 | Gordon Yung5 | Marshall Hertz6 | Kevin M. Chan7 | Matt Morrell8 | Hilary Goldberg9 | Suresh Vedantham10 | Mary Clare Derfler10 | Paul Commean11 | Keith Berman12 | Ed Spitznagel13 | Jeff Atkinson14 | George Despotis15

1Department of Medicine, Division of Pulmonology, Indiana University, Bloomington, Indiana, USA
2Department of Medicine, Division of Pulmonology, University of Iowa, Iowa City, Iowa, USA
3Department of Medicine, Division of Pulmonology, University of Alabama, Tuscaloosa, Alabama, USA
4Department of Medicine, Division of Pulmonology, Columbia University of Alabama, Orange Beach, Alabama, USA
5Division of Pulmonary, Critical Care, and Sleep Medicine, University of California San Diego, La Jolla, California, USA
6Department of Medicine, Division of Pulmonology, University of Minnesota, Minneapolis, Minnesota, USA
7Department of Medicine, Division of Pulmonology, University of Michigan, Ann Arbor, Michigan, USA
8Department of Medicine, Division of Pulmonology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
9Harvard Medical School, Department of Medicine, Division of Pulmonology, Brigham and Women's Hospital, Boston, Massachusetts, USA
10Clinical Coordinating Center, Washington University School of Medicine, Mallinckrodt Institute of Radiology, St. Louis, Missouri, USA
11Data Coordinating Center, Washington University School of Medicine, Mallinckrodt Institute of Radiology, St. Louis, Missouri, USA
12Health Research Associates, Mountlake Terrace, Washington, USA
13Department of Mathematics, Washington University, St. Louis, Missouri, USA
14Department of Internal Medicine, Division of Pulmonary Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
15Department of Pathology & Immunology, Division of Laboratory & Genomic Medicine, Department of Anesthesiology, Division of Cardiothoracic Anesthesiology, Washington University School of Medicine, St. Louis, Missouri, USA

Correspondence
George Despotis, Department of Pathology & Immunology, Division of Laboratory & Genomic Medicine, Washington University School of Medicine, 425 S. Euclid Avenue, Campus Box 8118, Saint Louis, MO 63110, USA.
Email: gjdespotis@wustl.edu

Funding information
US Centers for Medicare and Medicaid Services (CMS), Grant/Award Number: CAG-00324R2; TheraKos®, Inc., Grant/Award Number: NCT02181257

Abstract

**Background:** This study was designed to prospectively evaluate the efficacy of extracorporeal photopheresis (ECP) to attenuate the rate of decline of FEV1 in lung transplant recipients with refractory bronchiolitis obliterans. Due to an observed higher than expected early mortality, a preliminary analysis was performed.

**Study Design and Methods:** Subjects from 10 lung transplant centres were assigned to ECP treatment or to observation based on spirometric criteria, with potential crossover for those under observation. The primary endpoint of this study was to assess response to ECP (i.e., greater than a 50% decrease in the rate of FEV1 decline) before and 6 months after initiation of ECP. Mortality was also evaluated 6 and 12 months after enrolment as a secondary endpoint.
Results: Of 44 enrolled subjects, 31 were assigned to ECP treatment while 13 were initially assigned to observation on a non-random basis using specific spirometric inclusion criteria (seven of the observation patients subsequently crossed over to receive ECP). Of evaluable patients, 95% of patients initially assigned to treatment responded to ECP with rates of FEV\textsubscript{1} decline that were reduced by 93% in evaluable ECP-treated patients. Mortality rates (percentages) at 6 and 12 months after enrolment was 32% and 41%, respectively. The most common (92%) primary cause of death was respiratory or graft failure. Significantly (p = 0.002) higher rates of FEV\textsubscript{1} decline were observed in the non-survivors (−212 ± 177 ml/month) when compared to the survivors (−95 ± 117 ml/month) 12 months after enrolment. In addition, 18 patients with bronchiolitis obliterans syndrome (BOS) diagnosis within 6 months of enrolment had lost 38% of their baseline lung function at BOS diagnosis and 50% of their lung function at enrolment.

Conclusions: These analyses suggest that earlier detection and treatment of BOS should be considered to appreciate improved outcomes with ECP.

KEYWORDS
bronchiolitis obliterans syndrome, extracorporeal photopheresis, forced expiratory volume in 1 s, lung transplantation

INTRODUCTION

Chronic lung allograft dysfunction (CLAD), predominantly related to bronchiolitis obliterans syndrome (BOS) represents the leading cause of morbidity and mortality in recipients of lung allografts beyond the first year\textsuperscript{1} with an annual incidence that exceeds 7%–8% in the first 10 years after transplantation.\textsuperscript{2} BOS is an irreversible fibro-proliferative immune process that results in progressive narrowing of bronchial lumens, ultimately resulting in complete airway occlusion.\textsuperscript{3} Despite current clinical use of one or more on or off-label treatment options, no immunosuppressive regimen has been shown to consistently prevent BOS.\textsuperscript{4,5}

Extracorporeal photopheresis (ECP), a pheresis-based therapeutic immunomodulatory intervention, was approved by the FDA in 1987 for the management of cutaneous T-cell lymphoma.\textsuperscript{6} ECP is additionally covered by Medicare for two off-label uses: management of GVHD after bone marrow transplantation\textsuperscript{7,8} and for cellular rejection of orthotopic heart transplants.\textsuperscript{9}

Since the early 1990s, ECP has also been used on an off-label basis for treatment of BOS refractory to the currently available armamentarium of immunosuppressive agents in lung transplant recipients.\textsuperscript{10–16} Three retrospective analyses have demonstrated a reduction in the rate of decline of lung function in ~80% of lung transplant recipients with BOS.\textsuperscript{14–16} Based on these findings, we submitted a formal request to the US Centres for Medicare and Medicaid (CMS) to revise its ECP National Coverage Determination (NCD) to cover this treatment for patients with refractory BOS.

Pursuant to concerns raised by CMS regarding the study design for a prospective trial, we pursued a follow-up analysis of our previously published 60-patient database\textsuperscript{16} to address these issues. In this re-analysis, FEV\textsubscript{1} was the only parameter that correlated with outcome (e.g., 50% survival at 1 year for patients with an FEV\textsubscript{1} < 1.25 L when compared to 85% survival at 1 year for patients with an FEV\textsubscript{1} > 1.25 L, p < 0.0001).\textsuperscript{17} In addition, two parameters associated with response to ECP were identified in this analysis: patients with an FEV\textsubscript{1} rate of decline that exceeded 40 ml/month were 12 times more likely to respond to ECP and patients who had a statistically significant (p < 0.05) rate of FEV\textsubscript{1} decline over time (via linear regression analysis) were 10 times more likely to respond to ECP when compared to those patients whose rate of FEV\textsubscript{1} decline over time was not statistically significant (p > 0.05).

Under its Medicare Coverage and Evidence Development (CED) authority, CMS published a Decision Memo\textsuperscript{18} authorising use of ECP for treatment of Medicare patients with BOS in the setting of an approved research protocol. In September 2012, CMS approved our prospective, multi-centre registry study with a target enrolment of 160 patients over 5 years to attain our primary spirometric rate of decline endpoint (50% decrease in the rate of decline in FEV\textsubscript{1} between a 6-month period before and after enrolment).\textsuperscript{19} After 1 year of enrolment (n = 44), despite improvement in rate of decline in FEV\textsubscript{1} observed in the entire cohort, a higher than expected mortality rate was also observed within the first year after enrolment. Therefore, a preliminary analysis was performed with the primary aim of assessing the factors associated with early mortality before completion of the 6-month ECP regimen. Since the protocol construct did not allow patients to receive ECP treatment unless they met defined spirometric criteria, we also wanted to compare the survival between patients who were non-randomly assigned to the either the ECP treatment versus Observation cohorts.
2 | MATERIALS AND METHODS

2.1 | Subjects

Subjects were enrolled in an ongoing, multicentre, study involving Medicare lung transplant recipients diagnosed with BOS that was refractory to conventional therapy, and therefore eligible to be treated with ECP. Subjects were recruited from nine centres from April 2015 to July 2016.19 This study protocol (NCT 02181257) was initially approved by the Washington University Human Research Protection Office and subsequently by all local IRBs at enrolling centres.

2.2 | Refractory BOS diagnosis and treatment regimens

All subjects enrolled in this study received prophylactic standard immunosuppressive therapy pursuant to local practices at enrolling institutions. Pulmonary function was monitored by serial spirometry following lung transplant in accordance with guidelines issued by the American Thoracic Society (ATS).20 BOS diagnoses were rendered using clinical criteria predicated by FEV1 values as defined by the International Society for Heart and Lung Transplantation.21 Enrolling sites had full discretion to administer any new therapy and/or augment the current immunosuppressive regimen after diagnosis of BOS. Refractory BOS was defined as a progressive decline in FEV1 unresponsive to all interventions as determined by the enrolling investigator.

2.3 | Registry study design

2.3.1 | Subject assignment and crossover

Enrolled subjects were initially assigned to one of two (ECP vs. Observation) cohort on a non-randomised basis predicated on the spirometric criteria previously described:32; subjects who met the spirometric criteria (i.e., a statistically significant rate of FEV1 decline that exceeded 10 ml/month if the most recent pre-ECP FEV1 was <1200 or 30 ml/month if FEV1 > 1200 ml) were assigned to the ECP Treatment cohort. Subjects who were enrolled in the study but who did not initially meet these spirometric criteria were assigned to the Observation cohort. For subjects in the Observation cohort who continued to have FEV1 values regularly monitored after enrolment, ECP treatment could be initiated when the subject's FEV1 values subsequently met the aforementioned spirometric criteria; these Observation cohort subjects were designated post hoc as a “Crossover.”

2.3.2 | ECP regimen and instruments utilised

Subjects that met the enrolment spirometric rate of decline criteria either initially (ECP Treatment cohort) or with Crossover (Observation cohort) were scheduled to receive 24 ECP treatments over a period of 6 months, using a regimen previously described.9 In summary, treatment centres performed ECP using the intravenous formulation of 8 methoxy psoralin (UVADEX™) with either the UVA XTS or CELLEX instruments (Therakos, Exton, PA) predicated on instrument availability, patient-specific indications or operator experience.

2.4 | Spirometry data (FEV1) between cohorts

2.4.1 | FEV1

Spirometry was performed in clinical laboratories at each enrolling site according to ATS guidelines. FEV1 data for enrolled subjects were summarised for assigned cohorts at several time points: baseline (as defined by ISHLT guidelines), 1st screen (the first of at least 5 FEV1 values measured 6 months prior to ECP), enrolment, and monthly (when available) up to 12 months after ECP initiation.

2.4.2 | FEV1 rate of decline

To assess the relative efficacy of ECP to arrest the rate of decline in lung function, the rate of decline in FEV1 was calculated via linear regression using five FEV1 values obtained 6 months prior to enrolment, and using at least four FEV1 values obtained at 6 and 12 months after ECP initiation predicated on availability of FEV1 values 2 months after the first ECP procedure. Only patients who had at least three monthly FEV1 values after the first ECP treatment were included in the comparative analysis. The change in rate of decline between the pre and post-ECP periods was calculated as the difference between the slope of FEV1 decline post-ECP (e.g., 3, 6 or 12 months) and the rate of decline just prior to ECP initiation (slope_post-ECP - slope_pre-ECP).

2.5 | Primary efficacy outcome

The primary endpoint of the Registry study was the change in rate of FEV1 decline with “response” defined as a 50% or greater decrease in the rate of FEV1 decline between pre-ECP and 6 months post-ECP treatment.

2.6 | Secondary outcomes

2.6.1 | Relationship between initial rate of FEV1 decline and response to ECP

To assess the ability of our spirometric enrolment criteria to identify subjects who respond to ECP, “response” at 3 or 6 months after ECP was summarised for ECP and Observation Crossover Cohort subjects; predictive indices with respect to the ability of spirometric enrolment criteria to identify response were derived using Bayes’ Theorem.
2.6.2 | Mortality assessment

As part of our DSMB safety assessment functions, mortality was adjudicated with respect to relatedness to ECP by our DSMB while causality was assessed by local managing physicians. Time to mortality was determined for all subjects who expired within 12 months of enrolment and early mortality was defined as death prior to completion of the 6-month ECP regimen (i.e., 24 ECP procedures). The following factors were assessed with respect to a potential association with early mortality: demographics, indication, and type of transplant, the rate and degree of decline of pulmonary function at enrolment. In addition, response to ECP and study design-related factors (i.e., spirometric enrolment criteria) were also evaluated.

2.7 | Requisite time for BOS diagnosis on enrolment FEV₁ values

To characterise the impact of the requisite time for BOS on the magnitude of decline in FEV₁ at enrolment, % change from baseline FEV₁ values were summarised at various times point in a subset (n = 18) of patients who were initially assigned to ECP treatment whose BOS diagnosis was made within 6 months prior to enrolment.

2.8 | Statistical methods

Chi square and Fischer’s exact test were used to compare orical variables. Either two-sample Wilcoxon rank-sum or one-way analysis of variance was used for comparison of continuous variables at one or more time periods. In circumstances where there were missing data (in part related to early mortality), specific data points were displayed in distribution plots rather than mean values and when data were expressed as mean values in tables, the number of data points for each condition was included.

Univariate linear regression was used to evaluate the decline in lung function via generation of slope values using time (independent variable) and FEV₁ values (dependent variable) at multiple different time periods. Univariate and multivariate linear regression analyses were performed to identify potential covariates that may be associated with mortality at either 6 or 12 months after enrolment and with response to ECP therapy; only variables that had a p value <0.1 with univariate analyses were included in multivariate models. A p value of <0.05 was considered statistically significant. Statistical analyses were performed using STATA14 software (StataCorp, College Station, TX).

3 | RESULTS

3.1 | Subject enrolment and assignment

Of 44 patients enrolled in the ECP Registry Study, 31 were initially assigned to the ECP cohort while 13 were assigned to the Observation cohort in a non-randomised fashion based on spirometric enrolment criteria. Thirty-seven subjects received ECP as follows: 30 of 31 ECP Treatment cohort patients received ECP (one excluded due to venous access issues) while 6 of 7 observation cohort subjects who crossed over received ECP therapy (Crossover Cohort) (see Figure 1). The average number of days between enrolment and the first ECP treatment was 10 days for ECP cohort subjects while Crossover subjects received ECP on average 28 days after observation cohort enrolment; this 18 day difference translated into an average loss of 51 ml in FEV₁.

3.2 | Patient demographics, indication for lung transplant and immunosuppressive regimen

Demographic, primary disease indication for transplant, type of lung transplant (i.e., single vs. bilateral), and stage of BOS at enrolment were similar between the two cohorts (Table 1). A substantial percentage of patients were in advanced stages (58% vs. 50% in Stage II/III in the ECP and Observation cohorts, respectively).

A similar overall distribution of maintenance immunosuppressive medications was observed between cohorts (Table 2). Accordingly, similar percentages of patients had received either Azithromycin or anti-thymocyte globulin between the two cohorts, with p values of 0.3 and 1.0, respectively (Table 2).

3.3 | Spirometric analyses: FEV₁ and FEV₁ rates of decline

Table 3 summarises FEV₁ values at four time points in each cohort (ECP vs. observation vs. crossover). When compared to the ECP cohort, the screening FEV₁ was statistically lower (p < 0.01) in the observation subjects who did not cross-over to ECP treatment.

Table 4 summarises rates of FEV₁ decline and p values (i.e., values derived from the FEV₁ versus time plots and slopes expressed in ml/month) between cohorts at two time points (before and 6 months after enrolment); the number of data points included was predicated on availability of FEV₁ measurements as detailed at the bottom of the table. As expected based on the spirometric criteria for cohort...
The slopes of FEV1 decline pre-enrolment were much steeper ($p = 0.004$) in the ECP cohort ($−192 ± 167 \text{ ml/month}$) when compared to the observation cohort ($−46 ± 46 \text{ ml/month}$).

### Outcomes

#### 3.4.1 Primary outcome: Assessment of spirometric “response”

The primary outcome of the registry study with respect to the change in the rate of FEV1 decline could only be assessed in a subset of enrolled patients that had at least six monthly FEV1 values after ECP treatment as follows: 63% (19 of 30) of ECP cohort subjects and 71% (5 of 7) Cross-over subjects. At 6 months, 19 evaluable ECP cohort subjects demonstrated a 93% decrease (from $/C_0136$ to $/C_010 \text{ ml/month}$, $p = 0.0002$) in the mean rate of FEV1 decline after ECP (Table 4, Figure 2). In contrast, only a trend ($p = 0.29$) in reduced mean rate of FEV1 decline (65%) 6 months after ECP was observed in 5 initially assigned Observation patients who crossed over to ECP treatment (Table 4).

Using a 50% or more decrease in the rate of FEV1 decline as a response criteria, 95% (18 of 19 evaluable subjects) of subjects initially assigned to ECP treatment responded to ECP. A statistically ($p = 0.001$) lower percentage (25% or 2 of 8 evaluable subjects) of Observation subjects responded to ECP. Of six Observation subjects who crossed over and received ECP treatment, only five were evaluated as one subject did not have enough FEV1 values after crossover due to early mortality. Of these 5 evaluable Crossover subjects, two demonstrated no change in the rate of FEV1 decline at 6 months after ECP (Table 4, see Figures E2 and E3 for Crossover subjects). Of three evaluable non-
3.5 Secondary outcomes

3.5.1 Assessment of spirometric enrolment criteria to identify patients who responded to ECP

Of 36 patients who received ECP (30 ECP and 6 Crossover), 24 patients (19 ECP Treatment and 5 Observation with crossover) had six monthly post-enrolment FEV1 values. Of six Observation patients, three had at least three monthly post-enrolment FEV1 values. Data from these 27 patients were used to assess the predictive capacity (using Bayes Theorem derived predictive indices like sensitivity) of the spirometric enrolment criteria to identify response to ECP (the spirometric primary endpoint). Predictive indices for a response to ECP using the initial assignment as directed by the spirometric enrolment criteria are as follows: Sensitivity: 90%, Specificity: 85%, Positive Predictive Value: 94%, and Negative Predictive Value: 75% (see Figure 3).

3.5.2 Mortality analysis

Of 44 subjects, 32% (12 ECP and 2 Crossover) expired within 6 months of enrolment while 43% (15 ECP and 3 Crossover and one Observation) expired within 12 months of enrolment. There were no treatment related deaths as adjudicated by our DSMB.

TABLE 3 Spirometry FEV1 values prior to and after enrolment between non-randomised cohorts allocated to either ECP treatment or observation based on spirometric criteria

<table>
<thead>
<tr>
<th></th>
<th>All patients (n = 44)</th>
<th>ECP cohort (n = 31)</th>
<th>Observation cohort (n = 13)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline FEV1 after transplant</td>
<td>2.7 ± 0.9</td>
<td>2.8 ± 0.9</td>
<td>2.7 ± 0.5</td>
</tr>
<tr>
<td>First screening FEV1</td>
<td>2.0 ± 0.8</td>
<td>2.2 ± 0.8</td>
<td>1.8 ± 0.8</td>
</tr>
<tr>
<td>Enrolment</td>
<td>1.4 ± 0.6</td>
<td>1.4 ± 0.6</td>
<td>1.6 ± 0.6</td>
</tr>
<tr>
<td>Last FEV1 after enrolment</td>
<td>1.0 ± 0.5</td>
<td>1.0 ± 0.6</td>
<td>1.0 ± 0.4</td>
</tr>
</tbody>
</table>

Note: FEV1 in L and data expressed as mean ± SD. Abbreviation: ECP, extracorporeal photopheresis.
*aBaseline values based on data from 40 subjects.

TABLE 4 Rates of FEV1 decline prior to and after enrolment between non-randomised cohorts allocated to either ECP treatment or observation based on spirometric criteria

<table>
<thead>
<tr>
<th>Time after enrolment</th>
<th>ECP cohort (n = 30)</th>
<th>Observation cohort (n = 13)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 (ECP: n = 30, CO: n = 7, No CO: n = 6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV1 rate of decline</td>
<td>−148 ± 154</td>
<td>−38 ± 51</td>
</tr>
<tr>
<td>p value</td>
<td>0.009 ± 0.01</td>
<td>0.12 ± 0.08</td>
</tr>
<tr>
<td>0+ months (ECP: n = 19, CO: n = 5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV1 rate of decline</td>
<td>−136 ± 117</td>
<td>−81 ± 36</td>
</tr>
<tr>
<td>p value</td>
<td>0.01 ± 0.01</td>
<td>0.08 ± 0.11</td>
</tr>
<tr>
<td>6 months (ECP: n = 19, CO: n = 5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV1 rate of decline</td>
<td>−10 ± 58e</td>
<td>−28 ± 98</td>
</tr>
<tr>
<td>p value</td>
<td>0.18 ± 0.13e</td>
<td>0.1 ± 0.12</td>
</tr>
</tbody>
</table>

Note: Linear regression derived values (slope and p values) from FEV1 versus time relationship. Slopes (ml/month) and p values expressed as mean ± SD. 0+ refers to either at enrolment (ECP cohort) or at Crossover (observation cohort).

Abbreviations: CO, observation patients who cross over to ECP treatment; ECP, extracorporeal photopheresis.
*aOnly 6 of 7 crossover subjects included since one did not receive ECP.

*p < 0.01 when compared to ECP cohort.
description of the etiology of mortality between cohorts at various time periods is summarised in Table 5. The most common primary cause of death among all non-survivors (both ECP cohort and Observation cohort subjects) was respiratory or graft failure (90%). There was no difference in mortality between the two cohorts ($p = 0.2$). Although a higher numeric percentage of subjects initially assigned to ECP treatment ($n = 31$) expired at both 6 (ECP: 39% vs. Obs: 23%) and 12 (ECP: 48% vs. Obs: 31%) months after enrolment when compared to subjects initially assigned to Observation ($n = 13$), these trends were not significant $p = 0.49$ and $p = 0.34$, respectively. These findings were not unexpected as they were most likely related to subject assignment in a non-random fashion using spirometry-based criteria which assigned subjects to ECP treatment based on higher rates of FEV1 decline.

### 3.5.3 | Comparison of spirometry between survivors and non-survivors

To evaluate the potential effects of reduced lung function on survival, FEV1 values were compared at several time points between patients who survived for either 6 or 12 months (Survivors) versus those who expired in that period of time (Non-survivors). Specifically, 14 and 19 subjects who expired had higher mean FEV1 at the first screening FEV1 prior to enrolment when compared lower mean FEV1 in 40 and 36 subjects who survived ($p = 0.01$) 6 and 12 months after enrolment, respectively. These findings were explained by the comparison of rate of decline in FEV1 between survival cohorts. Significantly ($p = 0.009$) higher rates of FEV1 decline were observed in the non-survivors ($-232 \pm 195$ ml/month) when compared to the survivors ($-101 \pm 110$ ml/month) at 6 months and similarly at 12 months after enrolment ($p = 0.002$) (Table S1). When all relevant covariates were included in a multivariate logistic regression analysis to identify potential variables associated with either early mortality or 12 month mortality, only pre-enrolment FEV1 rate of decline in lung function was associated with both early (6 month) ($p = 0.005$) and 12 month mortality ($p = 0.005$).

### 3.6 | The impact of requisite time for BOS diagnosis on enrolment FEV1

To assess the impact of the requisite time for BOS diagnosis on lung function at enrolment, mean FEV1 values obtained during the 6 month
period prior to and at enrolment were calculated for 18 patients who had a diagnosis of BOS within the 6 month FEV1 screening period. Figure 4 illustrates that patients had lost an average of 38% of their lung function at the time of BOS diagnosis (on average at 2 months prior to enrolment), with further reduction to an average of 50% of baseline lung function by enrolment. Accordingly, the mean time for diagnosis on average 3–4 months. This information prompted us to send a survey to our enrolling centres requesting the typical institutional frequency for laboratory spirometry for the BOS surveillance population. A review of responses from 6 of 10 enrolling centres revealed a median spirometry monitoring frequency of 3 months (range: 1–6 months) for enrolled patients after the first year of transplant at our enrolling centres.
Although ECP was associated with a 93% reduction in the rate of decline in FEV1 at 6 months after ECP initiation in our non-randomised registry study, we also observed a concerning early mortality rate. Safety of the ECP procedure was assessed by our DSMB which adjudicated that none of the fatal outcomes were related to ECP and local investigators characterised that 92% were due to end-stage pulmonary dysfunction. Although higher than expected mortality was observed after enrolment in patients non-randomly assigned to ECP Treatment based on spirometry criteria, these findings were related to the more aggressive nature of BOS in patients assigned to ECP treatment (i.e., statistically significant fourfold greater rate of FEV1 decline in patients assigned to ECP treatment) which was shown to be the most important and only factor associated with mortality; this artefact was clearly related to the study design since spirometric criteria were used to assign patients to treatment in a non-randomised fashion with those assigned to ECP having a resultant much greater rate of FEV1 decline. With respect to our study design, our current analysis revealed that our spirometric criteria enabled accurate identification of responders to ECP. In the Observation cohort involving patients with low rates of FEV1 decline, only two subjects (25%) of eight evaluable subjects (crossover and non-crossover) had a 50% change in the enrolment FEV1 rate of decline. Poor treatment response in a slow FEV1 decline phenotype was originally described by Jackson et al. in a large series of patients with BOS and more recently confirmed with another analysis. We also confirmed that the current spirometric enrolment criteria can detect patients who respond to ECP and should not have a substantial clinical impact with respect to delay in ECP treatment since the time for crossover was nominal (18 days) with minimal loss of FEV1 volume in that period.

The findings of low FEV1 values at BOS diagnosis (Figure 4) and the higher rates of decline in FEV1 in non-survivors highlights the potential importance of early detection and expedited management of BOS with ECP as first line therapy rather than use for refractory disease to arrest disease progression before lung function reaches a critically level. Accordingly, we have modified our CMS approved study to now include a randomised controlled trial (RCT) arm that involves use of ECP as first line therapy when compared to local standard of care management of BOS.

Delays in detection of BOS may also be an important factor that led to higher early mortality in our series. Generally, FEV1 measurements are made biweekly or monthly during the first year following lung transplant, with variable extension to every 3, 6, or 12 months between institutions, despite a fairly consistent annual BOS incidence of at least 7%–8% per year. Data from our previous publication demonstrate that this approach results in loss of up to 1 L of FEV1 volume at the diagnosis of BOS as well as a prolonged delay (mean = 401 days) for ECP initiation at our institution.

Accordingly, earlier detection of BOS via frequent spirometry coupled with earlier use of ECP or other new therapies may result in better functional status and prolonged survival for either primary or refractory BOS. However, use of a frequent monitoring schedule (every 4–8 weeks) for conventional laboratory spirometry over a long surveillance period (i.e., up to 15 years) may not be feasible for many patients, especially for patients who live far from their treatment or diagnostic facilities or who are not compliant with laboratory-based spirometry predicated on safety concerns in the setting of the current COVID-19 pandemic. Home Spirometry monitoring systems can lead to early detection of acute rejection and infection in lung transplant recipients, and may also be preferable if these systems can automatically transmit spirometric and symptom data to facilitate discrimination of variance results between infections versus rejection.

Despite our findings that support use of ECP in lung transplant recipients with BOS, there were several limitations to our registry study. The most notable involved the use of ECP for refractory BOS rather than at initial diagnosis of BOS, but also includes lack of a control comparator cohort to assess important outcomes, premature assessment of efficacy of ECP to attenuate the rate of decline of lung function, lack of uniform prophylactic and BOS treatment anti-rejection regimens, the lack of use of a standardised approach for early detection of BOS, and the inclusion of only Medicare patients. Although Medicare patients are typically older aged, age was not identified as a confounder with respect to attenuation of the rate of FEV1 decline by ECP or survival. These limitations and our preliminary analyses prompted us to revise the study to promote early detection (i.e., with use of an automated Home Spirometry Method) and treatment of refractory BOS at early stages and to evaluate all of the outcomes CMS had previously outlined: the impact of ECP on rate of decline in FEV1, survival and quality of life in a RCT arm using ECP as first-line therapy when compared to local Standard of Care.

In summary, these preliminary analyses support earlier detection and treatment of BOS especially in patients who have a rapid decline in lung function. In light of the preliminary suggestion of ECP’s efficacy in reducing the rate of decline of lung function, we are modifying our study to add an RCT arm that will enrol patients with newly diagnosed BOS. Based on these findings, we will continue to utilise our spirometric criteria to enrol patients who are more likely to respond to ECP.

ACKNOWLEDGMENTS
Funded by Therakos®, Inc., a Mallinckrodt Pharmaceuticals company (NCT02181257). The US Centers for Medicare and Medicaid Services (CMS) reimbursed costs of extracorporeal photopheresis therapy for enrolled participants in this CMS-approved study under its Coverage with Evidence Development authority (CAG-00324R2).

CONFLICT OF INTEREST
Relationships with entities related to the topic listed below: Chadi Hage, MD—None. Julia Klesney-Tait, MD—None. Keith Wille, MD—None. Selim Arcasoy, MD, MPH—None. Gordon Yung, MD—Financial interest that exceeds $5000 with Industry sponsor. Marshall Hertz, MD—None. Kevin Chan, MD—None. Matt Morrell, MD—None. Hilary Goldberg, MD—Subcontract for CMS and Therakos, Inc sponsored study. Suresh Vedantham, MD—Investigator of study funded by both Medicare and Therakos/Mallinckrodt (outlined above). Mary Clare
REFERENCES


19. CMS Protocol Number CAG-00324R2; ClinicalTrials.gov identifier: NCT02181257.


**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.

**How to cite this article:** The EPI Study Group, Hage CA, Klesney-Tait J, Wille K, et al. Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction. *Transfusion Medicine*. 2021;31:292–302. [https://doi.org/10.1111/tme.12779](https://doi.org/10.1111/tme.12779)